Obermatt
See Similar Stocks →

Lipocine

NAQ:LPCN · US53630X2036
PharmaceuticalsSmall

360

39
Profit price92
Owner Earnings Yield100
Dividend Yield1
Price/Sales16
Price/Book61
Return on Capital24
Return on Equity18
Profit margins23

Cash truth not applicable for financial companies.

Sales growth5
Profit growth79
Reinvestment4
Price momentum10
Debt load96
Debt serviceability10
Liquidity39
Analyst ratings22
Opinion Changes50
Price Target Upside88
Market mood1
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Lipocine doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees24
Websitelipocine.com
ISINUS53630X2036
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ObesityNeurologyPsychiatryHepatologyEndocrinologyCentral Nervous SystemBiotechnologyMedicalPharmaceutical

Description

Lipocine Inc. (Lipocine) operates as a clinical-stage biopharmaceutical company. The company is engaged in research and development for the delivery of drugs using its proprietary delivery technology. The company's principal operation is to provide o…

Analysis

Middle-of-the-road

Lipocine Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
4
2026

All-time high

28

Mar 2026

All-time low

4

Jun 2026

Average rank

16

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
16
—
—
—
Price/Earnings
—
—
—
—
Price/Book
61
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
25
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Lipocine with its peers
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Supernus Pharma
NMQ:SUPN
81
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aquestive Therapeutics
NMQ:AQST
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →